Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.49 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | RHEB | Q15382 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 9/20 | 0.44 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.42 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2570360 | 0.80 | CYP19A1 (0.62) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL28267390 | 0.79 | CHEK2 (0.61) | CHEK2CYP19A1RHEBPKN1PKN2 | |
| SCHEMBL8410194 | 0.76 | CHEK2 (0.81) | CHEK2RHEBPKN1PKN2 | |
| SCHEMBL6511501 | 0.76 | DHODH (0.47) | CHEK2DHODHPRMT5PDE4APDE4B | |
| SCHEMBL6062255 | 0.75 | RHEB (0.54) | CHEK2RHEBPKN1PKN2 | |
| SCHEMBL6061899 | 0.74 | CYP19A1 (0.53) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL8412123 | 0.74 | RHEB (0.59) | CHEK2RHEBPKN1PKN2 | |
| SCHEMBL8409891 | 0.72 | CHEK2 (0.70) | CHEK2RHEBPKN1PKN2 | |
| SCHEMBL31289493 | 0.72 | CHEK2 (0.61) | CHEK2DHODHPRMT5 | |
| SCHEMBL3333407 | 0.72 | RHEB (0.68) | CHEK2RHEBPKN1PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050148646-A1 | Dicationic triaryl analogs as anti-protozoan agents | BOYKIN DAVID W (US) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148646-A1 | Dicationic triaryl analogs as anti-protozoan agents | DDT, DDC, DARS1 | CHEK2 2931/4885CYP19A1 3935/4885CYP11B1 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.